vimarsana.com
Home
Live Updates
VALNEVA: Valneva Reports Full Year 2022 Results and Provides Corporate Updates : vimarsana.com
VALNEVA: Valneva Reports Full Year 2022 Results and Provides Corporate Updates
Total revenues of €361.3 million in 2022 compared to €348.1 million in 2021 Driven by product sales of €114.8 million (82.3% increase compared to 2021), including €85.2 million of travel vaccine sales
Related Keywords
Japan ,
Finland ,
Australia ,
Thailand ,
France ,
New Zealand ,
Sweden ,
United Kingdom ,
United Arab Emirates ,
Denmark ,
Austria ,
Germany ,
Bulgaria ,
United States ,
Brazil ,
Bahrain ,
Canada ,
Switzerland ,
America ,
Scotland ,
Kingdom Of Bahrain ,
Japanese ,
Deerfield Orbimed ,
Instituto Butantan ,
Joshua Drumm ,
Vivalis Intercell ,
Tropical Disease Priority Review Voucher Program ,
Vaccines Announce European Partnership For Marketing ,
Global Communications ,
Drug Administration ,
European Commission For Valneva Inactivated ,
Pan American Health Organization ,
European Medicines Agency ,
Pfizer ,
Us Department Of Defense ,
European Union Member States ,
European Commission ,
European Union ,
Deerfield Management Company Orbimed ,
Coalition For Epidemic Preparedness Innovations ,
Euronext Paris ,
Chief Financial Officer ,
Biologics License Application ,
Prescription Drug User Fee Act ,
Epidemic Preparedness Innovations ,
Breakthrough Therapy ,
Priority Review Voucher ,
North America ,
Fast Track ,
Against Lyme ,
Outdoor Recreationists ,
Good Clinical Practice ,
United Arab ,
Valneva Sweden ,
Deerfield Management Company ,
European Investor ,
Global Investor Relations ,
Announces Closing ,
Global Offering ,
Announces Upsized Financing Arrangement ,
Funds Deerfield ,
Chikungunya Vaccine License Application ,
Priority Review ,
Initiates Rolling Submission ,
License Application ,
Single Shot Chikungunya Vaccine Candidate ,
Successfully Completes Pivotal Phase ,
Single Shot Chikungunya Vaccine ,
Reports Positive ,
Month Antibody Persistence Data ,
Announces Initiation ,
Adolescent Phase ,
Completes Enrollment ,
Disease Priority Review Voucher Program ,
Pfizer Report Six Month Antibody Persistence Data ,
Lyme Disease Vaccine Candidate ,
Valneva Initiate Phase ,
Pfizer Report Further Positive Phase ,
Including Booster Response ,
Valneva Issue Update ,
Trial Evaluating Lyme Disease Vaccine Candidate ,
Pfizer Enter ,
Equity Subscription Agreement ,
Update Terms ,
Collaboration Agreement ,
Fifth Disease ,
Prescribing Information ,
Medication Guide ,
Enterotoxigenic Escherichia ,
Receives Marketing Authorization ,
Inactivated Whole Virus ,
Receives Conditional Marketing Authorization ,
Receives Emergency Use Authorization ,
Confirms Amendment ,
Advance Purchase Agreement ,
Provides Clinical ,
Regulatory Updates ,
Announce European Partnership ,
Diese Gold Aktie ,
Sichern Sie ,
Valneva ,
Reports ,
Bull ,
Ear ,
022 ,
Results ,
Rovides ,
Corporate ,
Updates ,
vimarsana.com © 2020. All Rights Reserved.